DUPIXENT: payments to doctors
Payments that named DUPIXENT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $185.7M
- Providers
- 82,131
- Transactions
- 1,356,584
- Average per transaction
- $137
The per-transaction average — $137 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 82,131 providers the average total is $2,261, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $103,927,500 | 56.0% |
| Regeneron Healthcare Solutions, Inc. | $72,899,973 | 39.3% |
| Sanofi-aventis U.S. LLC | $4,377,310 | 2.4% |
| Regeneron | $4,029,951 | 2.2% |
| Sanofi US Services Inc. | $442,021 | 0.2% |
| Sanofi Pasteur Inc. | $3,422 | 0.0% |